MedTrace Logo

Methemoglobinemia Following Intravenous Iron Treatment

NCT06309641 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-12-09

No results posted yet for this study

Summary

Methemoglobinemia as a side effect of treatment with intravenous iron has not previously been described. This study aims to assess methemoglobin levels in patients with anemia following treatment with intravenous iron, administered as ferric carboxymaltose or ferric derisomaltose.

Conditions

  • Methemoglobinemia
  • Anemia
  • Iron Deficiencies
  • Side Effect

Interventions

DIAGNOSTIC_TEST

Blood sample after treatment

Blood samples for measurement of methemoglobin are obtained directly before and 30-120 minutes after drug administration.

OTHER

Case reports

Description of clinical course and methemoglobin levels in patients with severe anemia who developed methemoglobinemia after intravenous administration of ferric derisomaltose.

Sponsors & Collaborators

  • Claudia Seiler

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-02
Primary Completion
2025-10-13
Completion
2025-10-13

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06309641 on ClinicalTrials.gov